Detalhe da pesquisa
1.
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
J Dtsch Dermatol Ges
; 18(6): 582-609, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32489011
2.
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
Cancer Immunol Immunother
; 68(5): 765-772, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30806748
3.
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.
Cancer Immunol Immunother
; 67(5): 825-834, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29487980
4.
Fear of cancer progression in patients with stage IA malignant melanoma.
Eur J Cancer Care (Engl)
; 27(5): e12901, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30126009
5.
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis.
Cancer Immunol Immunother
; 65(8): 951-9, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27294607
6.
[Rare cutaneous side effect of vemurafenib : Fever and exanthema 14 days after therapy initiation]. / Seltene kutane Nebenwirkung unter Vemurafenib : Fieberhaftes Exanthem 14 Tage nach Einleitung der Therapie.
Hautarzt
; 72(11): 1014-1016, 2021 Nov.
Artigo
em Alemão
| MEDLINE | ID: mdl-33856494
7.
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
J Dtsch Dermatol Ges
; 14(7): 662-81, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27373241
8.
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD-1-Antikörper beim metastasierten Melanom - ein Update.
J Dtsch Dermatol Ges
; 18(6): 582-609, 2020 Jun.
Artigo
em Alemão
| MEDLINE | ID: mdl-32519497
9.
Ipilimumab in patients with cancer and the management of dermatologic adverse events.
J Am Acad Dermatol
; 71(1): 161-9, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24767731
10.
[67-year-old male with cervical lymph node swelling : Preparation for the specialist examination: part 45]. / 67/m mit einer zervikalen Lymphknotenschwellung : Vorbereitung auf die Facharztprüfung: Folge 45.
Hautarzt
; 70(Suppl 1): 72-74, 2019 Apr.
Artigo
em Alemão
| MEDLINE | ID: mdl-30976882
11.
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
Melanoma Res
; 34(1): 44-53, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37962220
12.
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
J Cancer Res Clin Oncol
; 150(5): 252, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38743104
13.
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Eur J Cancer
; 200: 113536, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38306840
14.
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
Eur J Cancer
; 199: 113505, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262306
15.
Palliative treatment of skin metastases in dermato-oncology.
J Dtsch Dermatol Ges
; 11(11): 1041-5; quiz 1046, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24015966
16.
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial).
J Cancer Res Clin Oncol
; 149(13): 11705-11718, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37405475
17.
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.
Eur J Cancer
; 179: 87-97, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36509002
18.
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.
J Immunother Cancer
; 11(9)2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37730278
19.
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
Eur J Cancer
; 176: 88-99, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36198246
20.
Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases.
Data Brief
; 45: 108676, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36426068